These results showed that improvement of cell therapy by PD-1 blockade was dependent on host T cells irrespective of the parental tumor, target antigen, tumor PD-L1 expression, or anti-PD-1-antibody timing. The gene discussed is PDCD1; the disease is neoplasm.